Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline.
Priya PatelPaula D RobinsonMarie CohenKatie A DevinePaul GibsonMark T HoldsworthEloise NeumannAndrea OrseyRobert PhillipsDaniela SpinelliJennifer ThackrayMarianne van de WeteringDeborah WoodsSandra CabralLillian SungL Lee DupuisPublished in: Pediatric blood & cancer (2022)
This clinical practice guideline provides recommendations for preventing acute and delayed phase chemotherapy-induced nausea and vomiting (CINV) in pediatric patients. The recommendations are based on two systematic reviews of randomized controlled trials evaluating interventions to prevent (1) acute phase CINV and (2) delayed phase CINV. Recommendations for acute phase and delayed phase CINV prophylaxis are made for patients receiving chemotherapy of varying emetogenicity, as well as for patients not able to receive dexamethasone or a neurokinin-1 receptor antagonist. Evidence gaps, including antiemetic safety and optimal dosing, were identified.
Keyphrases
- chemotherapy induced
- liver failure
- end stage renal disease
- clinical practice
- systematic review
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- physical activity
- drug induced
- high dose
- intensive care unit
- hepatitis b virus
- radiation therapy
- rectal cancer
- acute respiratory distress syndrome
- locally advanced